| [1] |
Kenmotsu H, Tanigawara Y. Pharmacokinetics, dynamics and toxicity of docetaxel:Why the Japanese dose differs from the Western dose[J].Cancer Sci,2015,106 (5):497-504.
|
| [2] |
Onoue H, Yano I, Tanaka A, et al. Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach [J]. Eur J Clin Pharmacol,2016,72(6):703-710.
|
| [3] |
Syn NL, Wang L, Wong AL,et al. Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study [J]. Cancer Sci,2016,107(2):173-180.
|
| [4] |
Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel [J].Clin Pharmacokinet,1999,36(2):99-114.
|
| [5] |
Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase Ⅱstudies in patients with cancer [J]. J Clin Oncol,1998,16(1):187-196.
|
| [6] |
Sandström M, Lindman H, Nygren P,et al. Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients[J]. J Clin Oncol,2005,23(3):413-421.
|
| [7] |
Yano R, Konno A, Watanabe K, et al. Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase Ⅱand Ⅲtrials[J]. Int J Clin Oncol,2013,18(1):96-104.
|
| [8] |
Rosing H, Lustig V, van Warmerdam LJ, et al. Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion [J].Cancer Chemother Pharmacol,2000,45(3):213-218.
|
| [9] |
Krens SD, McLeod HL, Hertz DL. Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy[J].Pharmacogenomics,2013,14(5):555-574.
|
| [10] |
Bruno R, Vivier N, Veyrat-Follet C, et al. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel[J]. Invest New Drug,2001,19(2):163-169.
|
| [11] |
Hénin E, Meille C, Barbolosi D, et al. Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase Ⅰ/Ⅱtrial of docetaxel plus epirubicin in metastatic breast cancer patients [J]. Breast Cancer Res Treat,2016,156(2):331-341.
|
| [12] |
Capitain O, Asevoaia A, Boisdron-Celle M, et al. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing:a phaseⅡ, proof-of-concept study[J]. Clin Colorectal Cancer,2012, 11(4):263-267.
|
| [13] |
Kim WY,Woo SU,Seo JH,et al. Toxicities,dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases[J]. J Cancer Res Ther,2011,7(4):412-415.
|
| [14] |
Furlanetto J, Eiermann W, Marmé F,et al. Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study[J]. Ann Oncol,2016,27(11):2053-2059.
|
| [15] |
Beumer JH, Chu E, Salamone SJ, et al. Body-surface area-based chemotherapy dosing: appropriate in the 21st century? [J]. J Clin Oncol,2012,30(31):3896-3897.
|
| [16] |
Engels FK, Loos WJ, van der Bol JM, et al. Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study[J]. Clin Cancer Res,2011,17(2):353-362.
|
| [17] |
Kaldate RR, Haregewoin A, Grier CE, et al. Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6[J]. Oncologist,2012,17(3):296-302.
|
| [18] |
Chatelut E, White-Koning ML,Mathijssen RH,et al. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents[J]. Br J Cancer,2012,107(7):1100-1106.
|
| [19] |
Rudek MA, Sparreboom A, Garrett-Mayer ES, et al. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy[J]. Eur J Cancer,2004,40(8):1170-1178.
|
| [20] |
Minami H, Ohe Y, Niho S,et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and cisplatin in elderly and non-elderly patients:why is toxicity increased in elderly patients[J]. J Clin Oncol,2004,22(14):2901-2908.
|
| [21] |
Alexandre J, Rey E, Girre V, et al. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study [J]. Ann Oncol, 2007,18(1):168-172.
|
| [22] |
Ozawa K, Minami H, Sato H, et al. Clinical trial simulations for dosage optimization of docetaxel in patients with liver dysfunction,based on a log-binominal regression for febrile neutropenia [J].Yakagaku Zasshi,2009,129(6):749-757.
|